TB-500 vs VIP
Both TB-500 and VIP are used for anti-inflammatory. Here's how their evidence, dosing, and regulatory status actually compare.
TB-500
Evidence BThymosin Beta-4 Fragment
A synthetic fragment of thymosin beta-4 that promotes cell migration, blood vessel formation, and tissue repair. Often stacked with BPC-157 as the 'Wolverine Stack.'
View full TB-500 profile →VIP
Evidence BVasoactive Intestinal Peptide
A 28-amino-acid neuropeptide with broad immunomodulatory effects. Used clinically (intranasal) by some practitioners for chronic inflammatory response syndrome (CIRS).
View full VIP profile →Side-by-Side
| Attribute | TB-500 | VIP |
|---|---|---|
| Evidence Grade | B | B |
| FDA Status | Not FDA-approved — Category 2 (reclassification to Cat 1 expected 2026) | Not FDA-approved — investigational; ongoing trials for sarcoidosis |
| Typical Dose | 2 mg twice weekly (subcutaneous) | 50 mcg intranasal, 4 times daily (CIRS protocols) |
| Clinics Indexed | 183 | 24 |
| Categories | recovery, anti-inflammatory | anti-inflammatory, neuroprotection |
Key reported benefits — TB-500
- ✓Wound healing
- ✓Anti-inflammation
- ✓Tissue regeneration
- ✓Flexibility
Key reported benefits — VIP
- ✓Anti-inflammation
- ✓Pulmonary effects
- ✓Neuroprotection
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.